Company intelligence / Profile preview

Dicot Pharma AB

Ownership: Private
Employees: ~3
Development stage: Phase 2

Overview

The lead candidate LIB‑01 has completed Phase 1 with an excellent safety profile and clear efficacy signal. Phase 2 clinical studies are ongoing for erectile dysfunction. Preclinical work suggests potential in metabolic diseases. The company holds seven patent families with protection until at least 2042 in key markets like the US.

Therapeutic areas: Metabolic DisordersMen's Health
Modalities: small molecules
Industry: Biotech

Drug pipeline

1 asset

LIB-01

Partnerships

Collaborates with leading partners and renowned experts worldwide during development phase; specific partner names not disclosed as of latest reports

Beyond the preview

Go deeper on Dicot Pharma AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dicot Pharma AB.

Explore the full profile